Understanding the genetic alterations that lead to esophagus, pancreas, and liver cancer is essential to fighting the disease. At Fox Chase, a multidisciplinary team of researchers and clinicians meets regularly to review translational research initiatives to identify and characterize new biomarkers of esophagus, pancreas, and liver cancers that lead to new, innovative prevention and targeted therapy options for our patients.